Okay. All right. So then we can begin. Sorry about all the confusion everybody. We're going to kick it off right away in the interest of time. So we're pleased to be joined by the management from ...

Caspian Therapeutics was launched with $50 million to progress KO-7246 through IND-enabling development and early clinical evaluation in patients with diabetes. Menin inhibition is positioned as ...

Early clinical findings support menin inhibition as a promising approach for high-risk ALL, although ALL-specific data remain limited.

Panelists highlight that the emergence of menin inhibitors is reshaping the treatment paradigm for KMT2A-rearranged acute myeloid leukemia (AML), with ongoing research focused on optimizing their use, ...

The FDA has approved ziftomenib (Komzifti, Kura Oncology) for adults with relapsed or refractory (R/R) acute myeloid leukemia (AML) harboring a nucleophosmin 1 (NPM1) mutation, which occurs in up to ...

KMT2A-rearranged acute myeloid leukemia (AML) is a highly aggressive leukemia subtype characterized by poor prognosis and high relapse rates. Because the menin-MLL interaction is essential for the ...

Acute leukemia arises from genetic alterations within hematopoietic cells, which lead to unregulated cellular proliferation. Scientists have detected rearrangements of the lysine methyltransferase 2A ...

WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and ...

(RTTNews) - Biomea Fusion Inc. (BMEA) announced that it has presented new data from its COVALENT-111 study evaluating Icovamenib for type-2 diabetes at the 23rd World Congress on Insulin Resistance, ...

The MarketWatch News Department was not involved in the creation of this content. The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of ...